New imaging tracer could reveal hidden tumor hypoxia in prostate cancer
NCT ID NCT01567800
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a special PET scan tracer called 18F-FAZA to find low oxygen areas (hypoxia) in prostate tumors. Hypoxia can make cancer harder to treat with radiation or chemo. The study involved 18 men with intermediate to high-risk or metastatic prostate cancer. The goal was to see if this imaging method is feasible and could help plan better treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
18F-Fluoroazomycin Arabinoside (18F-FAZA) PET tracer
What this could lead to
If successful, this imaging method could help doctors see which parts of a prostate tumor have low oxygen, potentially guiding more effective radiotherapy or chemotherapy.
What could go wrong
This is a very small, early feasibility study with only 18 participants, so results may not apply to all patients. The tracer is only for imaging, not treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Health Network
Toronto, Ontario, M5G 2M9, Canada